IDH-targeted PET/MRI for diagnosing and grading gliomas
Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas
This project tests whether an IDH-targeted PET/MRI scan can find IDH mutations in adults with suspected or known glioma to help with diagnosis, grading, and treatment planning.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT07405372 on ClinicalTrials.gov |
What this trial studies
This observational study uses a PET/MRI protocol with an IDH-targeted tracer to image adult patients with suspected, newly diagnosed, or previously treated gliomas. Investigators will collect clinical and biological data, record PET metrics such as lesion location, size, SUVmax, and calculate target-to-background ratios, and compare imaging findings with pathological analysis including H&E and immunohistochemistry for IDH status. The goal is to build a noninvasive in vivo tracing platform and evaluation system to support precision diagnosis and prognostic evaluation. Imaging and pathology data will be correlated to determine how well the PET/MRI signature identifies IDH-mutant versus IDH-wildtype tumors.
Who should consider this trial
Good fit: Adults aged 18 or older with suspected, newly diagnosed, or previously treated glioma who can provide informed consent and tolerate MRI/PET imaging are ideal candidates.
Not a fit: Patients who cannot undergo MRI (for example due to incompatible implants or severe claustrophobia), pregnant or breastfeeding individuals, or those with recent excessive radiation exposure are not eligible and would not benefit from participation.
Why it matters
Potential benefit: If successful, this approach could allow noninvasive determination of IDH mutation status to guide more precise diagnosis, targeted therapy choices, and prognosis for glioma patients.
How similar studies have performed: Early preclinical work and some small clinical reports of IDH-targeted imaging have shown promise, but broad clinical validation remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient ≥ 18 years of age at the time of consent; * Patients with suspected, newly diagnosed, or previously treated gliomas; * Provided written informed consent authorisation before participating in the study. Exclusion Criteria: * Pregnancy or lactation; * MRI contraindications, not limited to cardiac implantable electronic devices and claustrophobia; * Participants with radiation exposure exceeding 50 mSv in the past year.
Where this trial is running
Chongqing, Chongqing Municipality
- Department of Nuclear Medicine, Daping Hospital of Army Medical University — Chongqing, Chongqing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Xiao Chen — Daping Hospital, Army Medical University
- Study coordinator: Xiao Chen
- Email: xiaochen229@foxmail.com
- Phone: 15922970174
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.